Abnormal post-prandial glucagon-like peptide release in patients with Crohn's disease

•What is already known on this subject?•Glucagon-like peptide (GLP)-1 and -2 have been shown to regulate immune responses in immune-mediated disorders, such as Crohn’s disease (CD)•What are the new findings?•Basal GLP-1 levels were up-regulated in CD, while GLP-1 secretion was significantly reduced compared to healthy volunteers (HV) and patients with metabolic syndrome (MS)•Post-prandial GLP secretion was positively correlated to insulin secretion indices, both in CD and MS•How might it impact on clinical practice in the foreseeable future?•Future research should focus on metabolic alterations and GLP secretion in patients with CD, as these may represent therapeutic targets